| Literature DB >> 23119178 |
Gerardo Alvarez-Uria1, Raghuprakash Reddy.
Abstract
Staphylococcus aureus (SA) is the most common cause of skin and soft tissue infections (SSTIs) and nosocomial infections. In developed countries there is a major concern about the rise of community-associated methicillin-resistant SA (CA-MRSA), but data from developing countries are scarce. In this study we describe the prevalence and antibiotic susceptibility of CA-MRSA and healthcare-associated MRSA (HA-MRSA) in a district hospital from rural India. We identified 119 CA-SA infections and 82 HA-SA infections. The majority of infections were SSTI, and the proportion of MRSA in CA-SA and HA-SA infections was 64.7% and 70.7%, respectively. The proportion of CA-MRSA in children <5 years was 73.7%. We did not observe any linezolid or vancomycin resistance. CA-SA had high levels of resistance to ciprofloxacin and low levels of resistance to chloramphenicol, doxycycline, rifampicin, and clindamycin. CA-MRSA had higher proportion of resistance to ciprofloxacin, erythromycin, gentamicin, and cotrimoxazole than CA methicillin-susceptible SA (CA-MSSA). HA-MRSA had higher proportion of resistance to clindamycin and doxycycline than CA-MRSA. The results of this study indicate that MRSA is replacing MSSA in CA-SA infections. If these findings are confirmed by other studies, the spread of CA-MRSA can be a major public health problem in India.Entities:
Year: 2012 PMID: 23119178 PMCID: PMC3478733 DOI: 10.5402/2012/248951
Source DB: PubMed Journal: ISRN Dermatol ISSN: 2090-4592
Percentage susceptibilities to antimicrobial agents of Staphylococcus aureus.
| Ciprofloxacin | Erythromycin | Clindamycin | Doxycycline | Gentamicin | Rifampicin | Cotrimoxazole | Chloramphenicol | |
|---|---|---|---|---|---|---|---|---|
| CA-SA, % (95% CI) | 25.2 (18.2–33.8) | 58.6 (49.4–67.3) | 87.1 (79.6–92.1) | 93.7 (87.3–97) | 74.6 (65.9–81.7) | 91.4 (82.8–95.9) | 55.2 (46–64) | 95.6 (89.8–98.2) |
| HA-SA, % (95% CI) | 19.8 (12.4–29.9) | 62 (50.8–72.1) | 75.9 (65.2–84.2) | 83.6 (72.6–90.7) | 78.2 (67.6–86.1) | 91.1 (80.1–96.3) | 58.8 (47.6–69.1) | 90.9 (82–95.6) |
| CA-SA versus HA-SA, | 0.368 | 0.634 | 0.045 | 0.03 | 0.56 | 0.953 | 0.619 | 0.189 |
| CA-MSSA, % (95% CI) | 42.9 (28.8–58.1) | 70.7 (55.1–82.6) | 92.3 (78.5–97.5) | 97.5 (84–99.7) | 92.9 (79.9–97.7) | 89.7 (72.2–96.7) | 78 (62.8–88.2) | 92.7 (79.5–97.6) |
| HA-MSSA, % (95% CI) | 33.3 (17.5–54.1) | 82.6 (61.6–93.4) | 95.7 (74.4–99.4) | 95 (71.4–99.3) | 95.7 (74.5–99.4) | 100 (93.5–81.5) | 69.6 (48.3–84.8) | 95.2 (72.5–99.3) |
| CA-MSSA versus HA-MSSA, | 0.446 | 0.292 | 0.605 | 0.611 | 0.654 | 0.17 | 0.452 | 0.698 |
| CA-MRSA, % (95% CI) | 15.6 (9–25.6) | 52 (40.7–63.1) | 84.4 (74.4–91) | 91.5 (82.3–96.2) | 64.5 (53–74.5) | 92.3 (81.1–97.1) | 42.7 (31.9–54.1) | 97.3 (89.6–99.3) |
| HA-MRSA, % (95% CI) | 14 (7.1–25.8) | 53.6 (40.5–66.2) | 67.9 (54.5–78.8) | 78.7 (64.6–88.2) | 70.9 (57.5–81.4) | 87.2 (72.5–94.6) | 54.4 (41.3–66.9) | 89.3 (78–95.1) |
| CA-MRSA versus HA-MRSA, | 0.803 | 0.859 | 0.024 | 0.046 | 0.439 | 0.417 | 0.182 | 0.063 |
| MSSA, % (95% CI) | 39.4 (28.3–51.7) | 75 (62.9–84.1) | 93.5 (83.9–97.6) | 96.7 (87.5–99.2) | 93.8 (84.6–97.7) | 93.5 (81.4–97.9) | 75 (62.9–84.1) | 93.5 (83.9–97.6) |
| MRSA, % (95% CI) | 14.9 (9.8–22.1) | 52.7 (44.1–61.1) | 77.4 (69.5–83.8) | 86.4 (78.9–91.6) | 67.2 (58.6–74.7) | 90.1 (81.9–94.8) | 47.7 (39.3–56.3) | 93.8 (88–96.9) |
| MSSA versus MRSA, | <0.001 | 0.003 | 0.006 | 0.032 | <0.001 | 0.51 | <0.001 | 0.947 |
| CA-MSSA versus CA-MRSA, | 0.001 | 0.05 | 0.231 | 0.216 | 0.001 | 0.684 | <0.001 | 0.252 |
| HA-MSSA versus HA-MRSA, | 0.046 | 0.016 | 0.009 | 0.1 | 0.016 | 0.122 | 0.212 | 0.418 |
CA: community associated; HA: health-care associated; SA: Staphylococcus aureus; MSSA: methicillin-susceptible Staphylococcus aureus; MRSA: methicillin-resistant Staphylococcus aureus; CI: confidence interval.